Adial Pharmaceuticals Dirección

Dirección controles de criterios 4/4

El CEO de Adial Pharmaceuticals' es Cary Claiborne , nombrado en Aug 2022, tiene una permanencia de 2.75 años. compensación anual total es $801.62K, compuesta por 58.1% salario y 41.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.95% de las acciones de la empresa, por valor de $59.28K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 7 años, respectivamente.

Información clave

Cary Claiborne

Chief Executive Officer (CEO)

US$801.6k

Compensación total

Porcentaje del salario del CEO	58.1%
Permanencia del CEO	2.1yrs
Participación del CEO	0.9%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Cary Claiborne en comparación con los beneficios de Adial Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$802k	US$466k	-US$7m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$1m	US$357k	-US$11m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$16m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$688k	US$15k	-US$19m

Compensación vs. Mercado: La compensación total ($USD801.62K) de Cary está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD679.79K).

Compensación vs. Ingresos: La compensación de Cary ha sido consistente con los resultados de la empresa en el último año.

CEO

Cary Claiborne (63 yo)

2.1yrs

Permanencia

US$801,621

Compensación

Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Cary Claiborne	CEO, President & Director	2.1yrs	US$801.62k	0.95% $ 63.8k
Joseph A. Truluck	CFO, Treasurer & Secretary	7.3yrs	US$389.03k	0.17% $ 11.1k
John Martin	Chief Legal Officer	3.7yrs	sin datos	sin datos
Andrew Taubman	Vice President of Corporate Development	no data	sin datos	sin datos
Catherine Fratila	Controller	3.7yrs	sin datos	sin datos

3.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ADIL se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Cary Claiborne	CEO, President & Director	2.8yrs	US$801.62k	0.95% $ 63.8k
Kevin Schuyler	Chairman & Lead Independent Director	8.4yrs	US$60.22k	0.10% $ 7.0k
James Newman	Independent Director	10yrs	US$56.22k	0.21% $ 14.2k
Robertson Gilliland	Independent Director	10yrs	US$53.22k	0% $ 0
J. Anderson	Independent Director	9.6yrs	US$59.22k	0% $ 0
Giovanni Addolorato	Chairperson of Scientific Advisory Board	5.8yrs	sin datos	sin datos
Tomáš Zima	Member of the Scientific Advisory Board	5.7yrs	sin datos	sin datos
Sebastian Mueller	Member of Scientific Advisory Board	5.7yrs	sin datos	sin datos

7.1yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de ADIL se considera experimentada (7 años de antigüedad promedio).

Adial Pharmaceuticals Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Independent Director recently bought US$67k worth of stock

Recent updates

Adial Pharmaceuticals, Inc. Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

New major risk - Financial position

Adial Pharmaceuticals, Inc. Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend Ip Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $4.28365 million.

Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding

Price target decreased by 19% to US$21.00

New major risk - Share price stability

Price target decreased by 17% to US$17.00

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Adial Pharmaceuticals, Inc. announced delayed amended 10-Q filing

Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding

Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding

Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals, Inc. announced delayed 10-Q filing

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

New major risk - Share price stability

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Compliance with Nasdaq Listing Rule 5550(b)(1)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Adial Clinical Trial: A Fluff Or A Win?

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial

Price target increased to US$10.67

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Independent Director recently bought US$67k worth of stock

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc.

Chairman recently bought US$55k worth of stock

Adial Pharmaceuticals, Inc. Announces Positive Pre-Clinical Data for PNV2 as A Drug Candidate for Triple Negative Breast Cancer

Director William Stilley has joined 3rd company board

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding from Bespoke Growth Partners, Inc., Keystone Capital Partners LLC

Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Adial Pharmaceuticals, Inc. announced that it has received $2.100003 million in funding from Keystone Capital Partners LLC, Bespoke Growth Partners, Inc., Rountop Limited Partnership, LLP and another investor

Forecast breakeven pushed back to 2024

Adial Pharmaceuticals Achieves 50% Enrollment in landmark ONWARD™ Phase 3 Trial

Adial Pharmaceuticals, Inc. to File Fast Track Application for Ad04 with the FDA

New 90-day high: US$3.19

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) completed the acquisition of Purnovate, LLC from the members of Purnovate.

New 90-day high: US$2.34

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) entered into an Equity Purchase Agreement to acquire Purnovate, LLC from the members of Purnovate.

Adial Pharmaceuticals, Inc. Announces Management and Board Changes, Effective December 14, 2020

Adial Pharmaceuticals, Inc. announced that it expects to receive funding from Keystone Capital Partners LLC

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Adial Pharmaceuticals, Inc. Announces That U.S. Food and Drug Administration Issues an Emergency Use Authorization for the Assure/Fastep® Covid-19 Igg/Igm Rapid Test Device

Adial Pharmaceuticals, Inc. Files for Expedited Review of AD04 with the FDA

Adial Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Bespoke Growth Partners, Inc.

New 90-day low: US$1.21

Adial Pharmaceuticals, Inc. and Iremedy Healthcare Companies, Inc. Partner to Sell Covid-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales

New 90-day low - US$1.32